ST. PAUL, Minn., May 14, 2025--(BUSINESS WIRE)--Ecolab Life Sciences has officially opened its new US Bioprocessing Applications Laboratory in King of Prussia, Pennsylvania. The new facility is designed to support biopharma customers with applications and process development for the purification of biotherapeutic molecules, providing comprehensive technical support to biopharmaceutical companies and contract manufacturers operating from small-scale to full commercial production. This new development location is well positioned in the Eastern U.S., close to many large pharmaceutical operations and a hub of bioprocessing innovation. The lab is equipped with high-throughput process development tools and manufacturing scale chromatography columns, enabling biotech firms to receive turnkey support for process development. Large biopharma companies can utilize the applications lab throughout the entire development cycle, from early to late stage and commercialization; including characterizing alternative resins to help reduce manufacturing costs and support with regulatory submissions. "Our new Bioprocessing Applications Lab marks a significant milestone in our ability to be a global technical partner to our customers around the world," said Jennifer Sorrells, Ph.D., vice president of research and development, Ecolab Life Sciences. "This facility demonstrates our commitment to delivering best-in-class bioprocessing solutions by pairing Ecolab’s innovative resin toolbox with deep domain expertise to optimize the purification process. We are dedicated to empowering our customers to accelerate the delivery of life-saving therapies to market." Biopharma and contract manufacturing organizations are already leveraging Ecolab’s Bioprocessing Applications Lab to help accelerate speed and enhance manufacturing efficiencies through lifecycle studies. The lab can initiate studies and deliver results within weeks, facilitating a faster route to market while providing customers with access to raw data and bench-level operations for transparency and collaboration. The new lab complements Ecolab’s existing European Applications and Research & Development Lab, in Wales, U.K., and is part of the Ecolab Life Sciences Pharma Center of Excellence, a multi-million dollar investment which also includes an interactive learning space, The Xchange customer experience center, and an API (Active Pharmaceutical Ingredient) and excipient manufacturing facility. Learn more here. About Ecolab A trusted partner for millions of customers, Ecolab (NYSE:ECL) is a global sustainability leader offering water, hygiene and infection prevention solutions and services that protect people and the resources vital to life. Building on more than a century of innovation, Ecolab has annual sales of $16 billion, employs approximately 48,000 associates and operates in more than 170 countries around the world. The company delivers comprehensive science-based solutions, data-driven insights and world-class service to advance food safety, maintain clean and safe environments, and optimize water and energy use. Ecolab’s innovative solutions improve operational efficiencies and sustainability for customers in the food, healthcare, high tech, life sciences, hospitality and industrial markets. Story Continues www.ecolab.com Follow us on LinkedIn @Ecolab, Instagram @Ecolab_Inc and Facebook @Ecolab. (ECL-C) View source version on businesswire.com: https://www.businesswire.com/news/home/20250514983408/en/ Contacts Joseph Durrant 651-250-4724 [email protected] View Comments
Ecolab Life Sciences Opens New State-of-the-Art Bioprocessing Applications Laboratory in Pennsylvania, US
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...